Tag: overpriced medication
Provisional finding in hydrocortisone competition case
First published by Author on March 28, 2019 in the following categories: Latest Market Sharing Price Fixing Price Hikes Pricing and tagged with cma | investigations | market abuse | marktet sharing | overpriced medication | Pharmaceuticals | price fixing | pricing
There’s been a provisional finding by the Competition and Markets Authority (CMA) in the important hydrocortisone competition case, with a Statement of Objections issued.
In the coming weeks, the CMA expect written and oral representations to be made following the Statement of Objections that’s been issued.
The provisional findings of the CMA are incredibly worrying. It all comes down whether the two companies at the heart of the investigation colluded in order to charge higher prices and make bigger profits; all at the expense of our NHS, and our hard-earned tax money.
Boots overcharging the NHS for pain-relief mouthwash
First published by Author on June 29, 2018 in the following categories: Investigations Price Hikes Pricing and tagged with cma | overpriced medication | pricing
Boots overcharging the NHS for pain relief mouthwash is a serious allegation that must be closely investigated.
The allegations are that the company behind high-street chain Boots, Walgreens Boots Alliance, are reportedly overcharging the NHS by almost 3,500% for pain-relieving mouthwash used by cancer patients.
The Competition and Markets Authority (CMA) are considering the issue and health Minister, Steve Brine, is calling for an urgent investigation.
Vital Hydrocortisone tablets at the centre of suspected excessive and unfair pricing to the NHS
First published by Admin on March 09, 2018 in the following categories: Price Hikes and tagged with nhs | overpriced medication
The Competition and Markets Authority (CMA) are investigating price-hikes of vital hydrocortisone tablets on the basis that they suspect they are being excessively inflated.
Intas Pharmaceuticals Limited and Accord Healthcare Limited, which acquired Actavis UK in January 2017, are at the centre of the CMA’s investigations. The suspicion is breaches of competition laws through unfair prices over the supply of hydrocortisone tablets in the UK to the NHS.
read more